Патология трансплантата печени в отдаленном посттрансплантационном периоде
https://doi.org/10.23873/2074-0506-2023-15-3-359-375
Аннотация
Ежегодно увеличивающееся количество трансплантаций печени и растущая популяция реципиентов, переживших ранний послеоперационный период, определяют актуальность изучения проблемы поздней дисфункции трансплантата. Многообразие возможных морфологических и функциональных нарушений пересаженной печени затрудняет их своевременную диагностику. Более того, у многих пациентов серьезное повреждение ткани трансплантата может длительно протекать без клинических проявлений и отклонений лабораторных параметров.
В статье приводится обзор и обобщение имеющихся данных о распространенности, структуре, факторах риска и прогностическом значении различных вариантов патологии печеночных трансплантатов, определяемых при гистологическом исследовании в отдаленные сроки после пересадки.
Об авторах
С. Э. Восканян
ФГБУ ГНЦ ФМБЦ им. А.И. Бурназяна ФМБА России
Россия
Россия
Сергей Эдуардович Восканян, член-корреспондент РАН, проф., д-р мед. наук, заместитель главного врача по хирургической помощи – руководитель Центра хирургии и трансплантологии
123098, Москва, ул. Маршала Новикова, д. 23
В. Е. Сюткин
ФГБУ ГНЦ ФМБЦ им. А.И. Бурназяна ФМБА России; ГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского ДЗМ»
Россия
Россия
Владимир Евгеньевич Сюткин, д-р мед. наук, профессор кафедры хирургии с курсами онкохирургии, эндоскопии, хирургической патологии, клинической трансплантологии и органного доноства Медико-биологического университета инноваций и непрерывного образования; ведущий научный сотрудник отделения трансплантации печени
123098, Москва, ул. Маршала Новикова, д. 23
129090, Москва, Большая Сухаревская пл., д. 3
А. И. Сушков
ФГБУ ГНЦ ФМБЦ им. А.И. Бурназяна ФМБА России
Россия
Россия
Александр Игоревич Сушков, канд. мед. наук, заведующий лабораторией новых хирургических технологий
123098, Москва, ул. Маршала Новикова, д. 23
Ю. В. Восканян
ФГБУ ГНЦ ФМБЦ им. А.И. Бурназяна ФМБА России
Россия
Россия
Юлия Владимировна Восканян, врач-гастроэнтеролог поликлиники
123098, Москва, ул. Маршала Новикова, д. 23
А. Ю. Веселкова
ФГБУ ГНЦ ФМБЦ им. А.И. Бурназяна ФМБА России
Россия
Россия
Александра Юрьевна Веселкова, врач-патологоанатом патологоанатомического отделения
123098, Москва, ул. Маршала Новикова, д. 23
Список литературы
1. Kwong AJ, Ebel NH, Kim WR, Lake JR, Smith JM, Schladt DP, et al. OPTN/SRTR 2020 annual data report: liver. Am J Transplant. 2022;22(Suppl 2):204–309. PMID: 35266621 https://doi.org/10.1111/ajt.16978
2. Adam R, Karam V, Cailliez V, O Grady JG, Mirza D, Cherqui D, et al. 2018 annual report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation. Transpl Int. 2018;31(12):1293-1317. PMID: 30259574 https://doi.org/10.1111/tri.13358
3. Åberg F, Gissler M, Karlsen TH, Ericzon BG, Foss A, Rasmussen A, et al. Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study. Hepatology. 2015;61(2):668–677. PMID: 25266201 https://doi.org/10.1002/hep.27538
4. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. PMID: 28930295 https://doi.org/10.1038/nrgastro.2017.109
5. Sprinzl MF, Weinmann A, Lohse N, Tönissen H, Koch S, Schattenberg J, et al. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. Transpl Int. 2013;26(1):67–74. PMID: 23126674 https://doi.org/10.1111/j.1432-2277.2012.01576.x
6. Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". Am J Gastroenterol. 2010;105(3):613–620. PMID: 20040915 https://doi.org/10.1038/ajg.2009.717
7. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl. 2011;17(1):15–22. PMID: 21254340 https://doi.org/10.1002/lt.22198
8. Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl. 2009;15(12):1843–1851. PMID: 19938117 https://doi.org/10.1002/lt.21943
9. Lim LG, Cheng CL, Wee A, Lim SG, Lee YM, Sutedja DS, et al. Prevalence and clinical associations of posttransplant fatty liver disease. Liver Int. 2007;27(1):76–80. PMID: 17241384 https://doi.org/10.1111/j.1478-3231.2006.01396.x
10. Tejedor-Tejada J, Valenzuela EF, Muñoz RN, Gómez LH, García-Pajares F, Álvarez C, et al. De-novo nonalcoholic fatty liver disease at 5 years after liver transplantation: prevalence and predictive factors. Eur J Gastroen-terol Hepatol. 2021;33(3):399–406. PMID: 32317584 https://doi.org/10.1097/MEG.0000000000001736
11. Narayanan P, Mara K, Izzy M, Dierkhising R, Heimbach J, Allen AM, et al. Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation. Transplantation. 2019;103(1):e14–e21. PMID: 29994981 https://doi.org/10.1097/TP.0000000000002317
12. Choudhary NS, Saraf N, Dhampalwar S, Mishra S, Gautam D, Lipi L, et al. Nonalcoholic fatty liver disease in living donor liver transplant recipients: a histology-based study. J Clin Exp Hepatol. 2022;12(5):1328–1332. PMID: 36157151 https://doi.org/10.1016/j.jceh.2022.04.012
13. Saeed N, Glass L, Sharma P, Shannon C, Sonnenday CJ, Tincopa MA. Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant: systematic review and meta-analysis. Transplantation. 2019;103(11):e345–e354. PMID: 31415032 https://doi.org/10.1097/TP.0000000000002916
14. Losurdo G, Castellaneta A, Rendina M, Carparelli S, Leandro G, Di Leo A. Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients. Aliment Pharmacol Ther. 2018;47(6):704–714. PMID: 29359341 https://doi.org/10.1111/apt.14521
15. Duseja A, Nanda M, Das A, Das R, Bhansali A, Chawla Y. Prevalence of obesity, diabetes mellitus and hyperlipidaemia in patients with cryptogenic liver cirrhosis. Trop Gastroenterol. 2004;25(1):15–17. PMID: 15303464
16. Karam V, Sebagh M, Rifai K, Yilmaz F, Bhangui P, Danet C, et al. Quality of life 10 years after liver transplantation: the impact of graft histology. World J Transplant. 2016;6(4):703–711. PMID: 28058221 https://doi.org/10.5500/wjt.v6.i4.703
17. Pageaux GP, Bismuth M, Perney P, Costes V, Jaber S, Possoz P, et al. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? J Hepatol. 2003;38(5):629–634. PMID: 12713874 https://doi.org/10.1016/s0168-8278(03)00088-6
18. DiMartini A, Dew MA, Day N, Fitzgerald MG, Jones BL, deVera ME, et al. Trajectories of alcohol consumption following liver transplantation. Am J Transplant. 2010;10(10):2305–2312. PMID: 20726963 https://doi.org/10.1111/j.1600-6143.2010.03232.x
19. Rice JP, Eickhoff J, Agni R, Ghufran A, Brahmbhatt R, Lucey MR. Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis. Liver Transpl. 2013;19(12):1377–1386. PMID: 24115392 https://doi.org/10.1002/lt.23762
20. Burra P, Mioni D, Cecchetto A, Cillo U, Zanus G, Fagiuoli S, et al. Histological features after liver transplantation in alcoholic cirrhotics. J Hepatol. 2001;34(5):716–722. PMID: 11434618 https://doi.org/10.1016/s0168-8278(01)00002-2
21. Никогосова А.Д., Умрик Д.В., Цирульникова О.М. HBV-инфекция de novo у пациентов после трансплантации печени. Вестник трансплантологии и искусственных органов. 2022;24(3):37–41.
22. Восканян С.Э., Сюткин В.Е., Шабалин М.В., Артемьев А.И., Колышев И.Ю., Башков А.Н. и др. Серонегативный фиброзирующий холестатический гепатит С после ретрансплантации печени, проведенной по поводу нерезектабельных метастазов нейроэндокринного рака тонкой кишки. Трансплантология. 2020;12(4):319–331.
23. van der Eijk AA, Pas SD, de Man RA. Hepatitis E virus: A potential threat for patients with liver disease and liver transplantation. Best Pract Res Clin Gastroenterol. 2017;31(2):143–150. PMID: 28624102 https://doi.org/10.1016/j.bpg.2017.03.006
24. Vij M, Rammohan A, Rela M. Longterm liver allograft fibrosis: A review with emphasis on idiopathic post-transplant hepatitis and chronic antibody mediated rejection. World J Hepatol. 2022;14(8):1541–1549. PMID: 36157865 https://doi.org/10.4254/wjh.v14.i8.1541
25. Londoño MC, Souza LN, Lozano JJ, Miquel R, Abraldes JG, Llovet LP, et al. Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients. J Hepatol. 2018;69(3):626–634. PMID: 29709679 https://doi.org/10.1016/j.jhep.2018.04.012
26. Shaikh OS, Demetris AJ. Idiopathic posttransplantation hepatitis? Liver Transpl. 2007;13(7):943–946. PMID: 17600346 https://doi.org/10.1002/lt.21202
27. Neil DA, Hubscher SG. Current views on rejection pathology in liver transplantation. Transpl Int. 2010;23(10):971–983. PMID: 20723179 https://doi.org/10.1111/j.1432-2277.2010.01143.x
28. Krasinskas AM, Demetris AJ, Poterucha JJ, Abraham SC. The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers. Liver Transpl. 2008;14(5):625–632. PMID: 18433038 https://doi.org/10.1002/lt.21404
29. Demetris AJ, Bellamy C, Hübscher SG, O'Leary J, Randhawa PS, Feng S, et al. 2016 Comprehensive update of the Banff working group on liver allograft pathology: introduction of antibody-mediated rejection. Am J Transplant. 2016;16(10):2816–2835. PMID: 27273869 https://doi.org/10.1111/ajt.13909
30. Levitsky J, Kaneku H, Jie C, Walsh RC, Abecassis M, Tambur AR. Donor-specific HLA antibodies in living versus deceased donor liver transplant recipients. Am J Transplant. 2016;16(8):2437–2444. PMID: 26896194 https://doi.org/10.1111/ajt.13757
31. O'Leary JG, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI. Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant. 2015;15(4):1003–1013. PMID: 25772599 https://doi.org/10.1111/ajt.13153
32. Kaneku H, O'Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant. 2013;13(6):1541–1548. PMID: 23721554 https://doi.org/10.1002/ajt.12212
33. O'Leary JG, Klintmalm GB. Impact of donor-specific antibodies on results of liver transplantation. Curr Opin Organ Transplant. 2013;18(3):279–284. PMID: 23591739 https://doi.org/10.1097/MOT.0b013e3283614a10
34. Gül-Klein S, Hegermann H, Röhle R, Schmelzle M, Tacke F, Schöning W, et al. Donor-specific antibodies against donor human leukocyte antigen are associated with graft inflammation but not with fibrosis long-term after liver transplantation: an analysis of protocol biopsies. J Inflamm Res. 2021;14:2697–2712. PMID: 34188517 https://doi.org/10.2147/JIR.S307778
35. Pinon M, Pizzol A, Chiadò C, David E, Chiusa L, Dell'Olio D, et al. Evaluation of graft fibrosis, inflammation, and donorspecific antibodies at protocol liver biopsies in pediatric liver transplant patients: a single-center experience. Transplantation. 2022;106(1):85–95. PMID: 33496554 https://doi.org/10.1097/TP.0000000000003649
36. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, Egawa H, Yurugi K, Masuda S, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl. 2012;18(11):1333–1342. PMID: 22888064 https://doi.org/10.1002/lt.23534
37. Taner T, Heimbach JK, Rosen CB, Nyberg SL, Park WD, Stegall MD. Decreased chronic cellular and antibodymediated injury in the kidney following simultaneous liver-kidney transplantation. Kidney Int. 2016;89(4):909–917. PMID: 26924059 https://doi.org/10.1016/j.kint.2015.10.016
38. Mells G, Mann C, Hubscher S, Neuberger J. Late protocol liver biopsies in the liver allograft: a neglected investigation? Liver Transpl. 2009;15(8):931–938. PMID: 19642126 https://doi.org/10.1002/lt.21781
39. Montano-Loza AJ, Mason AL, Ma M, Bastiampillai RJ, Bain VG, Tandon P. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15(10):1254–1261. PMID: 19790153 https://doi.org/10.1002/lt.21796
40. Mottershead M, Neuberger J. Transplantation in autoimmune liver diseases. World J Gastroenterol. 2008;14(21):3388–3395. PMID: 18528936 https://doi.org/10.3748/wjg.14.3388
41. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int. 2008;21(5):459–465. PMID: 18225996 https://doi.org/10.1111/j.1432-2277.2007.00628.x
42. Visseren T, Darwish Murad S. Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and autoimmune hepatitis after liver transplantation. Best Pract Res Clin Gastroenterol. 2017;31(2):187–198. PMID: 28624107 https://doi.org/10.1016/j.bpg.2017.04.004
43. Choudhary NS, Kumar N, Saigal S, Rai R, Saraf N, Soin AS. Liver transplantation for alcohol-related liver disease. J Clin Exp Hepatol. 2016;6(1):47–53. PMID: 27194896 https://doi.org/10.1016/j.jceh.2016.02.001
44. Choudhary NS, Saraf N, Dhampalwar S, Saigal S, Gautam D, Rastogi A, et al. Poor outcomes after recidivism in living donor liver transplantation for alcohol-related liver disease. J Clin Exp Hepatol. 2022;12(1):37–42. PMID: 35068783 https://doi.org/10.1016/j.jceh.2021.04.005
45. Goldschmidt I, Stieghorst H, Munteanu M, Poynard T, Schlue J, Streckenbach C, et al. The use of transient elastography and non-invasive serum markers of fibrosis in pediatric liver transplant recipients. Pediatr Transplant. 2013;17(6):525–534. PMID: 23802661 https://doi.org/10.1111/petr.12116
46. Hagan M, Asrani SK, Talwalkar J. Non-invasive assessment of liver fibrosis and prognosis. Expert Rev Gastroenterol Hepatol. 2015;9(10):1251–1260. PMID: 26377444 https://doi.org/10.1586/17474124.2015.1075391
47. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705–1713. PMID: 14698338 https://doi.org/10.1016/j.ultrasmedbio.2003.07.001
48. Della-Guardia B, Evangelista AS, Felga GE, Marins LV, Salvalaggio PR, Almeida MD. Diagnostic accuracy of transient elastography for detecting liver fibrosis after liver trannsplantation: a specific cut-off value is really needed? Dig Dis Sci. 2017;62(1):264–272. PMID: 27785710 https://doi.org/10.1007/s10620-016-4349-1
49. Ekong UD, Gupta NA, Urban R, Andrews WS. 20- to 25-year patient and graft survival following a single pediatric liver transplant-analysis of the United Network of Organ Sharing database: where to go from here. Pediatr Transplant. 2019;23(6):e13523. PMID: 31211487 https://doi.org/10.1111/petr.13523
50. Kelly D, Verkade HJ, Rajanayagam J, McKiernan P, Mazariegos G, Hübscher S. Late graft hepatitis and fibrosis in pediatric liver allograft recipients: current concepts and future developments. Liver Transpl. 2016;22(11):1593–1602. PMID: 27543906 https://doi.org/10.1002/lt.24616
51. Evans HM, Kelly DA, McKiernan PJ, Hübscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology. 2006;43(5):1109–1117. PMID: 16628633 https://doi.org/10.1002/hep.21152
52. Ekong UD, Melin-Aldana H, Seshadri R, Lokar J, Harris D, Whitington PF, et al. Graft histology characteristics in long-term survivors of pediatric liver transplantation. Liver Transpl. 2008;14(11):1582–1587. PMID: 18975292 https://doi.org/10.1002/lt.21549
53. Kosola S, Lampela H, Jalanko H, Mäkisalo H, Lohi J, Arola J, et al. Lowdose steroids associated with milder histological changes after pediatric liver transplantation. Liver Transpl. 2013;19(2):145–154. PMID: 23109058 https://doi.org/10.1002/lt.23565
54. Varma S, Ambroise J, Komuta M, Latinne D, Baldin P, Reding R, et al. Progressive fibrosis is driven by genetic predisposition, allo-immunity, and inflammation in pediatric liver transplant recipients. EBioMedicine. 2016;9:346–355. PMID: 27333038 https://doi.org/10.1016/j.ebiom.2016.05.040
55. Scheenstra R, Peeters PM, Verkade HJ, Gouw AS. Graft fibrosis after pediatric liver transplantation: ten years of follow-up. Hepatology. 2009;49(3):880–886. PMID: 19101912 https://doi.org/10.1002/hep.22686
56. . Markiewicz-Kijewska M, Szymańska S, Pyzlak M, Kaliciński P, Teisseyre J, Kowalski A, et al. Liver histopathology in late protocol biopsies after pediatric liver transplantation. Children (Basel). 2021;8(8):671. PMID: 34438562 https://doi.org/10.3390/children8080671
57. Neves Souza L, de Martino RB, Sanchez-Fueyo A, Rela M, Dhawan A, O'Grady J, et al. Histopathology of 460 liver allografts removed at retransplantation: a shift in disease patterns over 27 years. Clin Transplant. 2018;32(4):e13227. PMID: 29478248 https://doi.org/10.1111/ctr.13227
58. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825–832. PMID: 9121257 https://doi.org/10.1016/s0140-6736(96)07642-8
59. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1(5):431–435. PMID: 7308988 https://doi.org/10.1002/hep.1840010511
60. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696–699. PMID: 7560864 https://doi.org/10.1016/0168-8278(95)80226-6
61. Venturi C, Sempoux C, Bueno J, Ferreres Pinas JC, Bourdeaux C, Abarca-Quinones J, et al. Novel histologic scoring system for long-term allograft fibrosis after liver transplantation in children. Am J Transplant. 2012;12(11):2986–2996. PMID: 22882699 https://doi.org/10.1111/j.1600-6143.2012.04210.x
62. Venturi C, Sempoux C, Quinones JA, Bourdeaux C, Hoyos SP, Sokal E, et al. Dynamics of allograft fibrosis in pediatric liver transplantation. Am J Transplant. 2014;14(7):1648–1656. PMID: 24934832 https://doi.org/10.1111/ajt.12740
63. Fouquet V, Alves A, Branchereau S, Grabar S, Debray D, Jacquemin E, et al. Long-term outcome of pediatric liver transplantation for biliary atresia: a 10-year follow-up in a single center. Liver Transpl. 2005;11(2):152–160. PMID: 15666395 https://doi.org/10.1002/lt.20358
64. Egawa H, Miyagawa-Hayashino A, Haga H, Teramukai S, Yoshizawa A, Ogawa K, et al. Non-inflammatory centrilobular sinusoidal fibrosis in pediatric liver transplant recipients under tacrolimus withdrawal. Hepatol Res. 2012;42(9):895–903. PMID: 22524409 https://doi.org/10.1111/j.1872-034X.2012.01003.x
65. Rhu J, Ha SY, Lee S, Kim JM, Choi GS, Joh JW, et al. Risk factors of silent allograft fibrosis 10 years postpediatric liver transplantation. Sci Rep. 2020;10(1):1833. PMID: 32019996 https:// doi.org/10.1038/s41598-020-58714-z
66. Briem-Richter A, Ganschow R, Sornsakrin M, Brinkert F, Schirmer J, Schaefer H, et al. Liver allograft pathology in healthy pediatric liver transplant recipients. Pediatr Transplant. 2013;17(6):543–549. PMID: 23834615 https://doi.org/10.1111/petr.12119
67. Seyam M, Neuberger JM, Gunson BK, Hübscher SG. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence. Liver Transpl. 2007;13(7):966–974. PMID: 17370332 https://doi.org/10.1002/lt.21060
68. Erard-Poinsot D, Guillaud O, Hervieu V, Thimonier E, Vallin M, Chambon- Augoyard C, et al. Severe alcoholic relapse after liver transplantation: what consequences on the graft? A study based on liver biopsies analysis. Liver Transpl. 2016;22(6):773–784. PMID: 26929100 https://doi.org/10.1002/lt.24425
69. Dumortier J, Dharancy S, Cannesson A, Lassailly G, Rolland B, Pruvot FR, et al. Recurrent alcoholic cirrhosis in severe alcoholic relapse after liver transplantation: a frequent and serious complication. Am J Gastroenterol. 2015;110(8):1160–1167. PMID: 26169514 https://doi.org/10.1038/ajg.2015.204
70. Mourad MM, Algarni A, Liossis C, Bramhall SR. Aetiology and risk factors of ischaemic cholangiopathy after liver transplantation. World J Gastroenterol. 2014;20(20):6159–6169. PMID: 24876737 https://doi.org/10.3748/wjg.v20.i20.6159
71. Sebagh M, Rifai K, Féray C, Yilmaz F, Falissard B, Roche B, et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology. 2003;37(6):1293–1301. PMID: 12774007 https://doi.org/10.1053/jhep.2003.50231
72. Croome KP, Mathur AK, Aqel B, Yang L, Taner T, Heimbach JK, et al. Classification of distinct patterns of ischemic cholangiopathy following DCD liver transplantation: distinct clinical courses and long-term outcomes from a Multicenter cohort. Transplantation. 2022;106(6):1206–1214. PMID: 34468429 https://doi.org/10.1097/TP.0000000000003928
73. Сюткин В.Е., Салиенко А.А., Олисов О.Д., Новрузбеков М.С. Возврат аутоиммунных болезней после трансплантации печени. Трансплантология. 2022;14(4):421–431.
74. Ravikumar R, Tsochatzis E, Jose S, Allison M, Athale A, Creamer F, et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol. 2015;63(5):1139– 1146. PMID: 26186988 https://doi.org/10.1016/j.jhep.2015.07.005
75. Aguilar MT, Carey EJ. Current status of liver transplantation for primary biliary cholangitis. Clin Liver Dis. 2018;22(3):613–624. PMID: 30259857 https://doi.org/10.1016/j.cld.2018.03.011
76. Neuberger J. Recurrent primary biliary cirrhosis. Liver Transpl. 2003;9(6):539–546. PMID: 12783392 https://doi.org/10.1053/jlts.2003.50096
77. Vannas M, Arola J, Nordin A, Isoniemi H. Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: a step toward personalized immunosuppressive treatment. Medicine (Baltimore). 2022;101(2):e28509. PMID: 35029206 https://doi.org/10.1097/MD.0000000000028509
78. Manousou P, Arvaniti V, Tsochatzis E, Isgro G, Jones K, Shirling G, et al. Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transpl. 2010;16(1):64–73. PMID: 19866449 https://doi.org/10.1002/lt.21960
Рецензия
Для цитирования:
Восканян С.Э., Сюткин В.Е., Сушков А.И., Восканян Ю.В., Веселкова А.Ю. Патология трансплантата печени в отдаленном посттрансплантационном периоде. Трансплантология. 2023;15(3):359-375. https://doi.org/10.23873/2074-0506-2023-15-3-359-375
For citation:
Voskanyan S.E., Syutkin V.E., Sushkov A.I., Voskanyan Yu.V., Veselkova A.Yu. Liver allograft pathology in the late post-transplant period. Transplantologiya. The Russian Journal of Transplantation. 2023;15(3):359-375. (In Russ.) https://doi.org/10.23873/2074-0506-2023-15-3-359-375
Просмотров: 26
Послать статью по эл. почте 